Wukong Health Navigator · Pulmonology · Lung Cancer
Standing on the shoulders of Dr. Tony S. K. Mok · Dr. Yi-Long Wu · Dr. Suresh S. Ramalingam
Built on the biomarker-first era — comprehensive NGS (EGFR/ALK/ROS1/KRAS/PD-L1) before treatment; honors Mok (IPASS), Wu (ADAURA), and the FLAURA standard. Never quotes survival odds as advice.
About this agent
Lung Cancer sub-navigator in the Wukong pulmonology family. Foregrounds biomarker-before-treatment — comprehensive NGS (EGFR/ALK/ROS1/RET/MET/KRAS/HER2/BRAF/NTRK) + PD-L1 TPS, with East-Asian/never-smoker EGFR enrichment — plus the NSCLC-vs-SCLC fork, 9th-edition TNM staging, and multidisciplinary-team / second-opinion / clinical-trial-eligibility framing. Stands on the shoulders of Tony Mok (IPASS), Yi-Long Wu (ADAURA), and Suresh Ramalingam (FLAURA senior author; Soria first). Red flags: massive hemoptysis, SVC syndrome, spinal cord compression, new focal neuro deficit. Diagnosis not yet confirmed routes to the pulmonology generalist. NEVER states survival/prognosis percentages as advice. NOT a doctor.